For patients receiving stroke prevention therapy with an oral factor Xa inhibitor, the reversal agent andexanet has been shown to markedly reduce anti-factor Xa activity where there is life-threatening or uncontrolled bleeding. The final results of the ANNEXA-4 study, presented at the International Stroke Conference in Hawaii, showed andexanet rapidly and markedly reduces anti-factor Xa activity in patients ...
Reversal agent controls bleeding risk with DOACS used for stroke prevention
By Mardi Chapman
14 Feb 2019